Cargando…
Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standar...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530076/ https://www.ncbi.nlm.nih.gov/pubmed/34415556 http://dx.doi.org/10.1007/s12687-021-00541-4 |
_version_ | 1784801601664319488 |
---|---|
author | Abbott, Michael McKenzie, Lynda Moran, Blanca Viridiana Guizar Heidenreich, Sebastian Hernández, Rodolfo Hocking-Mennie, Lynne Clark, Caroline Gomes, Joana Lampe, Anne Baty, David McGowan, Ruth Miedzybrodzka, Zosia Ryan, Mandy |
author_facet | Abbott, Michael McKenzie, Lynda Moran, Blanca Viridiana Guizar Heidenreich, Sebastian Hernández, Rodolfo Hocking-Mennie, Lynne Clark, Caroline Gomes, Joana Lampe, Anne Baty, David McGowan, Ruth Miedzybrodzka, Zosia Ryan, Mandy |
author_sort | Abbott, Michael |
collection | PubMed |
description | Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standard genetic testing and trio-based whole genome sequencing (WGS), in the context of the Scottish Genomes Partnership (SGP) study. We also explored what users value about genomic sequencing. Insights from the costing and value assessments will inform a subsequent economic evaluation of genomic medicine in Scotland. An average cost of £1,841 per singleton was estimated for the standard genetic testing pathway, with significant variability between phenotypes. WGS cost £6625 per family trio, but this estimate reflects the use of WGS during the SGP project and large cost savings may be realised if sequencing was scaled up. Patients and families valued (i) the chance of receiving a diagnosis (and the peace of mind and closure that brings); (ii) the information provided by WGS (including implications for family planning and secondary findings); and (iii) contributions to future research. Our costings will be updated to address limitations of the current study for incorporation in budget impact modelling and cost-effectiveness analysis (cost per diagnostic yield). Our insights into the benefits of WGS will guide the development of a discrete choice experiment valuation study. This will inform a user-perspective cost–benefit analysis of genome-wide sequencing, accounting for the broader non-health outcomes. Taken together, our research will inform the long-term strategic development of NHS Scotland clinical genetics testing services, and will be of benefit to others seeking to undertake similar evaluations in different contexts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12687-021-00541-4. |
format | Online Article Text |
id | pubmed-9530076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-95300762022-10-05 Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland Abbott, Michael McKenzie, Lynda Moran, Blanca Viridiana Guizar Heidenreich, Sebastian Hernández, Rodolfo Hocking-Mennie, Lynne Clark, Caroline Gomes, Joana Lampe, Anne Baty, David McGowan, Ruth Miedzybrodzka, Zosia Ryan, Mandy J Community Genet Original Article Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standard genetic testing and trio-based whole genome sequencing (WGS), in the context of the Scottish Genomes Partnership (SGP) study. We also explored what users value about genomic sequencing. Insights from the costing and value assessments will inform a subsequent economic evaluation of genomic medicine in Scotland. An average cost of £1,841 per singleton was estimated for the standard genetic testing pathway, with significant variability between phenotypes. WGS cost £6625 per family trio, but this estimate reflects the use of WGS during the SGP project and large cost savings may be realised if sequencing was scaled up. Patients and families valued (i) the chance of receiving a diagnosis (and the peace of mind and closure that brings); (ii) the information provided by WGS (including implications for family planning and secondary findings); and (iii) contributions to future research. Our costings will be updated to address limitations of the current study for incorporation in budget impact modelling and cost-effectiveness analysis (cost per diagnostic yield). Our insights into the benefits of WGS will guide the development of a discrete choice experiment valuation study. This will inform a user-perspective cost–benefit analysis of genome-wide sequencing, accounting for the broader non-health outcomes. Taken together, our research will inform the long-term strategic development of NHS Scotland clinical genetics testing services, and will be of benefit to others seeking to undertake similar evaluations in different contexts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12687-021-00541-4. Springer Berlin Heidelberg 2021-08-20 2022-10 /pmc/articles/PMC9530076/ /pubmed/34415556 http://dx.doi.org/10.1007/s12687-021-00541-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Abbott, Michael McKenzie, Lynda Moran, Blanca Viridiana Guizar Heidenreich, Sebastian Hernández, Rodolfo Hocking-Mennie, Lynne Clark, Caroline Gomes, Joana Lampe, Anne Baty, David McGowan, Ruth Miedzybrodzka, Zosia Ryan, Mandy Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland |
title | Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland |
title_full | Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland |
title_fullStr | Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland |
title_full_unstemmed | Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland |
title_short | Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland |
title_sort | continuing the sequence? towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in scotland |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530076/ https://www.ncbi.nlm.nih.gov/pubmed/34415556 http://dx.doi.org/10.1007/s12687-021-00541-4 |
work_keys_str_mv | AT abbottmichael continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT mckenzielynda continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT moranblancaviridianaguizar continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT heidenreichsebastian continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT hernandezrodolfo continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT hockingmennielynne continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT clarkcaroline continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT gomesjoana continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT lampeanne continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT batydavid continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT mcgowanruth continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT miedzybrodzkazosia continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland AT ryanmandy continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland |